Can I stop taking venetoclax/venetoclax once I start taking it? What are the criteria for discontinuation of medication?

Venetoclax is an oral BCL-2 inhibitor, mainly used to treat hematological diseases such as chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). By inhibiting BCL-2 protein, venetoclax can restore the programmed death of tumor cells, thereby achieving therapeutic effects. After starting to use venetoclax, many patients will be concerned about whether they can stop using the drug and what the criteria are for stopping.

The use of Veneclax during treatment is not static. Depending on factors such as the patient's type of disease, response to treatment, and occurrence of side effects, doctors may decide whether to discontinue treatment with venetoclax. For patients with chronic lymphocytic leukemia (CLL), venetoclax is often combined with other drugs, such as ibrutinib or chemotherapy drugs, and the timing of discontinuation of the treatment regimen often depends on the patient's response and tolerability.

If the patient's condition is stable after a certain course of treatment and no recurrence is found in clinical testing, the doctor may recommend gradually stopping the medication. However, it should be noted that this decision is usually made after multiple reexaminations to confirm that the condition is in remission and there is no risk of recurrence. For patients with acute myeloid leukemia (AML), venetoclax is often used in combination with chemotherapy drugs. Criteria for discontinuation also need to be determined based on treatment response and risk of disease recurrence.

If the patient's condition is controlled during treatment and there are no signs of recurrence, the possibility of drug discontinuation is higher. However, after stopping the drug, patients need to be monitored regularly to ensure there is no recurrence. If relapse occurs or disease worsens during the discontinuation period, venetoclax treatment may need to be restarted or the treatment regimen may need to be adjusted.

In addition, the side effects of venetoclax are also an important factor affecting the decision to discontinue the drug. Common adverse reactions include hematological abnormalities such as leukopenia and neutropenia. Some patients may need to adjust the dose or suspend treatment because of these side effects. If the side effects are severe, the doctor may recommend temporarily stopping the medication or switching to other treatments to ensure patient safety and therapeutic effectiveness.

Reference materials:https://www.venclexta.com/